Evidence map›Paper›PMID 36982234›Full record

ArticleInternational journal of molecular sciences2023

Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer.

Bernhard Tribukait, Per-Olof Lundgren, Anders Kjellman, Ulf Norming, Claes R Nyman, Kiran Jagarlmundi, Ove Gustafsson

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Bernhard TribukaitDepartment of Oncology-Pathology, Karolinska Institute and University Hospital Solna, 141 86 Stockholm, Sweden.ORCID 0000-0002-2151-3097
Per-Olof LundgrenDepartment of Clinical Science, Intervention and Technology, Karolinska Institute and Karolinska University Hospital, 141 86 Stockholm, Sweden.ORCID 0000-0001-7976-6962
Anders KjellmanDepartment of Clinical Science, Intervention and Technology, Karolinska Institute and Karolinska University Hospital, 141 86 Stockholm, Sweden.
Ulf NormingDepartment of Clinical Science and Education, Södersjukhuset, 118 83 Stockholm, Sweden.
Claes R NymanDepartment of Clinical Science and Education, Södersjukhuset, 118 83 Stockholm, Sweden.
Kiran JagarlmundiResearch and Development Division, AroCell AB, 111 52 Stockholm, Sweden.ORCID 0000-0003-1567-5863
Ove GustafssonDepartment of Clinical Science, Intervention and Technology, Karolinska Institute and Karolinska University Hospital, 141 86 Stockholm, Sweden.
Karolinska University Hospital · SEStockholm South General Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymidine kinase 1 (TK1) is an intracellular enzyme involved in DNA-precursor synthesis. Increased serum TK1 levels are used as a biomarker in various malignancies. We combined serum TK1 with PSA and evaluated its capacity to predict overall survival (OS) in 175 men with prostate cancer (PCa), detected by screening in 1988-1989 (

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsBiomarkersHumansMaleThymidine KinaseBiomarkersProstate-Specific AntigenThymidine Kinasethymidine kinase 1biomarker integrationpredictionprostate cancerPSAsurvivalthymidine kinase 1

Identifiers

PMID36982234
PMCPMC10049218
OpenAlexW4323568303

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read24
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.